BOXBOROUGH, Mass.

马萨诸塞州博克斯伯勒

,

，

March 24, 2026

2026年3月24日

/PRNewswire/ -- Q-Square Business Intelligence, Corp. (Q2BI) today marked the independent launch of Janus Data Intelligence, Corp. (JDIX), a clinical AI technology company originally incubated within Q2BI. JDIX recently introduced two flagship platforms — JDIQ™ and JDIM™ — designed to enhance data quality, real-time monitoring, and intelligent decision-making across clinical development..

/PRNewswire/ -- Q-Square商业智能公司（Q2BI）今天标志着Janus数据智能公司（JDIX）的独立启动，这是一家最初在Q2BI内部孵化的临床人工智能技术公司。JDIX最近推出了两个旗舰平台——JDIQ™和JDIM™——旨在提升临床开发中的数据质量、实时监控和智能决策。

Continue Reading

继续阅读

Q2BI - A Global Clinical Data Intelligence Company

Q2BI - 全球临床数据智能公司

To learn more about JDIX and its newly launched platforms, visit:

要了解更多关于JDIX及其新推出的平台，请访问：

www.janusdi.com

www.janusdi.com

. Additional details regarding the announcement are available

有关该公告的更多详细信息，请参阅

here

这里

. Q2BI extends its sincere congratulations to the JDIX team as they embark on this important new chapter.

Q2BI向JDIX团队致以诚挚的祝贺，祝贺他们开启这一重要的新篇章。

Over the past three years, JDIQ™ and JDIM™ have been deployed across multiple biopharma clinical programs under Q2BI's incubation. Both platforms have been rigorously validated in real-world settings and have earned strong recognition from more than a dozen biopharma clients, with demonstrated impact on data quality, faster clinical data review cycles, and enhanced operational efficiency.

在过去的三年中，JDIQ™ 和 JDIM™ 在 Q2BI 的孵化下已部署于多个生物制药临床项目。这两个平台都在真实场景中经过了严格的验证，并获得了十多家生物制药客户的高度认可，展示了其在数据质量、更快的临床数据审查周期以及提升运营效率方面的显著影响。

Importantly, as JDIX begins operating independently, clients currently utilizing Q2BI's data visualization services can expect full continuity. These services remain unchanged, and Q2BI will continue to deliver them with the same level of quality, expertise, and reliability..

重要的是，随着 JDIX 开始独立运营，目前使用 Q2BI 数据可视化服务的客户可以期待完全的连续性。这些服务保持不变，Q2BI 将继续以相同的质量、专业性和可靠性提供服务。

A Strong Foundation

坚实的基础

Since its founding in 2009, Q2BI has completed over 1,800 clinical trial projects and contributed to more than 50 successful NDA/BLA submissions worldwide. This extensive track record reflects deep expertise in biometrics and clinical data, providing a strong foundation for continued innovation in AI-driven clinical development..

自 2009 年成立以来，Q2BI 已完成超过 1,800 个临床试验项目，并助力全球范围内 50 多个新药申请（NDA）/生物制品许可申请（BLA）成功提交。这一丰富的经验记录体现了其在生物统计和临床数据方面的深厚专业知识，为人工智能驱动的临床开发持续创新提供了坚实的基础。

AI and Data Science Investment

人工智能与数据科学投资

Since 2021, Q2BI has made significant strategic investments in artificial intelligence, establishing a dedicated Data Science Department with end-to-end AI research and development capabilities. These efforts have resulted in multiple AI-related invention patents, as well as the successful development of a suite of specialized AI tools and solutions tailored for clinical research..

自2021年起，Q2BI在人工智能领域进行了重要的战略投资，建立了专门的数据科学部门，具备端到端的人工智能研发能力。这些努力取得了多项与人工智能相关的发明专利，并成功开发出一套专为临床研究量身定制的专业人工智能工具和解决方案。

'JDIX reflects a direction we committed to several years ago—bringing AI closer to the day-to-day reality of clinical teams, not as a concept, but as something they can rely on,' said Gary Huang, Founder and CEO of Q2BI. 'What's most meaningful to us is seeing these technologies used in active clinical programs, where they help teams move faster, ask better questions, and make more confident decisions.'.

“JDIX 反映了我们几年前就已坚定承诺的方向——让人工智能更贴近临床团队的日常工作，不是作为一个概念，而是作为他们可以依赖的工具，”Q2BI 创始人兼首席执行官黄加里表示。“对我们来说，最有意义的是看到这些技术被应用于活跃的临床项目中，帮助团队更快行动、提出更好的问题，并做出更有信心的决策。”

Dual Innovation Tracks

双创新轨道

Today, Q2BI's statisticians and data scientists operate across two complementary innovation tracks, applying AI technologies to transform clinical development for biopharma companies and leveraging Q2BI's 17 years of biometrics expertise to help AI companies improve model accuracy, reliability, and scientific rigor.

今天，Q2BI的统计学家和数据科学家在两条互补的创新轨道上开展工作，应用人工智能技术来转变生物制药公司的临床开发，并利用Q2BI在生物统计学方面17年的专业经验，帮助人工智能公司提高模型的准确性、可靠性和科学严谨性。

Through this evolution, Q2BI has grown beyond its foundation as a biometrics CRO into a clinical data intelligence company serving both the life sciences and AI sectors..

通过这一演变，Q2BI已经超越了其作为生物识别CRO的根基，发展成为一家服务于生命科学和人工智能领域的临床数据智能公司。

As AI-driven methodologies continue to reshape the industry, Q2BI believes the coming decade will unlock new opportunities to accelerate and enhance global drug development. Q2BI remains committed to advancing clinical data intelligence and supporting the success of both life science innovators and AI technology leaders..

随着人工智能驱动的方法不断重塑行业，Q2BI相信未来十年将开启加速和提升全球药物开发的新机遇。Q2BI将继续致力于推进临床数据智能，并支持生命科学创新者和人工智能技术领导者取得成功。

About Q2BI

关于Q2BI

Q2BI is a global clinical data intelligence company specializing in biometrics, data science, and AI-enabled clinical solutions. With deep expertise across clinical statistics, data management, PK/PD, and regulatory submissions, Q2BI partners with biopharma and AI companies to accelerate the development of innovative medicines..

Q2BI是一家全球临床数据智能公司，专注于生物统计学、数据科学和人工智能赋能的临床解决方案。凭借在临床统计学、数据管理、药代动力学/药效动力学（PK/PD）以及监管提交方面的深厚专业知识，Q2BI与生物制药和人工智能公司合作，加速创新药物的开发进程。

For more information, visit

欲了解更多信息，请访问

www.q2bi.com

www.q2bi.com

Media Contact:

媒体联系人：

[email protected]

[email protected]

SOURCE Q-Square Business Intelligence (Q2BI)

来源 Q-Square 商业智能 (Q2BI)

21

21

%

%

more press release views with

更多新闻发布视图与

Request a Demo

请求演示